WO2014106805A3 - Fatty acid conjugates and their uses - Google Patents

Fatty acid conjugates and their uses Download PDF

Info

Publication number
WO2014106805A3
WO2014106805A3 PCT/IB2013/061385 IB2013061385W WO2014106805A3 WO 2014106805 A3 WO2014106805 A3 WO 2014106805A3 IB 2013061385 W IB2013061385 W IB 2013061385W WO 2014106805 A3 WO2014106805 A3 WO 2014106805A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
cancer
compounds
insulin resistance
disease
Prior art date
Application number
PCT/IB2013/061385
Other languages
French (fr)
Other versions
WO2014106805A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Publication of WO2014106805A2 publication Critical patent/WO2014106805A2/en
Publication of WO2014106805A3 publication Critical patent/WO2014106805A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome, cancer, a metabolic disease, a neurodegenerative disease and insulin resistance and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, neuropathic pain, hypertriglyceridemia, hyperglycemia, hyperinsulinemia, metabolic syndrome, cancer, metabolic disease, neurodegenerative diseases and insulin resistance.
PCT/IB2013/061385 2013-01-05 2013-12-28 Fatty acid conjugates and their uses WO2014106805A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN55CH2013 2013-01-05
IN55/CHE/2013 2013-01-05

Publications (2)

Publication Number Publication Date
WO2014106805A2 WO2014106805A2 (en) 2014-07-10
WO2014106805A3 true WO2014106805A3 (en) 2017-03-23

Family

ID=51062521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061385 WO2014106805A2 (en) 2013-01-05 2013-12-28 Fatty acid conjugates and their uses

Country Status (1)

Country Link
WO (1) WO2014106805A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
US20120184585A1 (en) * 2009-09-01 2012-07-19 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses
WO2012149352A1 (en) * 2011-04-29 2012-11-01 Catabasis Pharmaceuticals, Inc. Fatty acid guanidine and salicylate guanidine derivatives and their uses

Also Published As

Publication number Publication date
WO2014106805A2 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2011085643A8 (en) Fused pyridine derivatives
WO2014174425A3 (en) Compositions and methods for the treatment of orthostasis and neurological diseases
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014106805A3 (en) Fatty acid conjugates and their uses
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation
MX2019005568A (en) Compositions and methods for the treatment of gastrointestinal polyps.
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2014083476A3 (en) Compositions and methods for the treatment of metabolic and lipid disorders
WO2014122575A3 (en) Fatty acid conjugates for the treatment of inflammation and metabolic diseases
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13870244

Country of ref document: EP

Kind code of ref document: A2